alexa Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection.
Microbiology

Microbiology

Journal of Antivirals & Antiretrovirals

Author(s): Sakellariou GT, Chatzigiannis I

Abstract Share this page

Abstract Anti-TNFalpha therapy for rheumatic diseases appears to be safe in patients with chronic hepatitis C. However, the administration of anti-TNFalpha agents without initiation of prophylactic antiviral therapy (lamivudine 100 mg/day) in patients with chronic HBV infection results in exacerbation of liver disease. In this report, we describe our experience of long-term anti-TNFalpha therapy for ankylosing spondylitis in two inactive HBsAg carriers without preemptive antiviral treatment. This article was published in Clin Rheumatol and referenced in Journal of Antivirals & Antiretrovirals

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords